Specialty Pharma Journal Specialty, Precision & Technology
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) — A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer (NSCLC). Researchers utilized samples from the Phase 3 MARQUEE trial and found that the VeriStrat (VS) test was a significant predictor of outcomes, independent …
Tag Archives: Biodesix
August, 2018
May, 2015
-
22 May
Biodesix Launches its Liquid Biopsy Mutation Test for Lung Cancer Patients
Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer. The molecular diagnostics company announced the launch of GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The results from the blood test are …
March, 2015
-
11 March
Biodesix to Collaborate with Inivata for NGS-Based Lung Cancer Tests
Molecular diagnostics company Biodesix, Inc. is teaming up with clinical cancer genomics company Inivata to develop Next Generation Sequencing (NGS)-blood based tests for lung cancer. The companies announced their partnership to develop and commercialize these tests for clinical applications in lung cancer, leveraging Inivata’s proprietary, enhanced Tam-Seq technology platform and …